The biotech sector has delivered a blistering rally over the past year, leaving broader markets in the dust. The SPDR S&P Biotech ETF (XBI) has soared 61% in the last 12 months, while the S&P 500 advanced just 25% over the same period—underscoring a powerful rotation into innovative drugmakers.
Behind the momentum lies a wave of clinical breakthroughs, from gene-editing therapies to targeted treatments for hard-to-treat diseases. As these innovations move from lab to clinic, companies with strong pipelines and clear commercial strategies stand to benefit most. Among them, CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX) have emerged as front-runners, each offering distinct catalysts for the months ahead.
CRISPR Therapeutics, a leader in the gene-editing space, has already brought its first product to market. Casgevy, developed in partnership with Vertex, is approved for two rare blood disorders. While sales are still in the early innings, the trajectory points toward steady ramp-up.
But the real story lies in its pipeline. Two candidates are drawing particular attention:
With $2.4 billion in cash and equivalents as of March 31—against a market cap of roughly $5 billion—CRISPR has ample runway to fund its pipeline even if setbacks occur. Should its late-stage programs deliver positive results, the stock could see significant upside.
Vertex has long been the undisputed king of cystic fibrosis (CF), the only company offering medicines that address the root cause of the disease. But the narrative is shifting as Vertex aggressively expands into new therapeutic areas.
Vertex’s stock has lagged the broader biotech rally over the past year, weighed down by clinical setbacks and mixed quarterly results. Still, its dominant CF franchise provides a solid earnings base, while its pipeline offers multiple shots at growth. For long-term investors, the risk-reward profile looks increasingly attractive.
The second half of 2026 brings critical inflection points for both companies. CRISPR expects data readouts for CTX611 and CTX310, while Vertex awaits regulatory decisions on povetacicept. With the biotech sector enjoying strong tailwinds, these two names are well-positioned to capitalize on the next wave of innovation.
